Inventories are available on share folders, with different accesses to ensure confidentiality when necessary.

The inventory of marketed products containing S-SVHC and SRA is carried out every year. It covers the whole Solvay portfolio of marketed products World Wide on the basis of composition managed in SAP-EH&S tool. Each GBU validates the inventory of their own portfolio.

We must indeed maximize the chances of avoiding the use of S-SVHC as from R&I steps. Identification of substances belonging to S-SVHC/SRA reference lists takes place at the different stages of a R&I project and from the screening and incubation phase of the preliminary assessment. The WeGo innovation process includes requirements related to the tracking of S-SVHC/SRA and their risk management. If an S-SVHC is identified an Analysis of Safe Alternative (ASA) has to be performed.

No, R&I products are not included in the global inventories; they are managed separately within the WeGo or similar R&I process processes (see other question related to R&I)

ASA means Analysis of Safer Alternatives.

According the Solvay policy on S-SVHC management, BU’s BUs and industrial sites must identify Substances of Very High Concern (S-SVHC) in their activities and strive to substitute them with safer alternatives when it is technologically and socio-economically sustainable. 

The target is to identify for each use of product whether the S-SVHC can be replaced or enough reduced to avoid effects on health and environment.

A recommended template of ASA is available to carry out this analysis.

It is not mandatory to make ASA for the products containing yellow substances. However, depending on the potential concern or long term impact on the business or market , the GBU can decide to do it for few some of them.

No, there is no pre-defined target in terms of number of substituted products. But Syensqo 's target is to complete 100% of risk assessments and analysis of safer alternatives for marketed products containing S-SVHC within the year of the inventory. Regular reviews are highly recommanded (every 3 years). According to the Syensqo policy, GBUs should strive to substitute S-SVHC with safer alternatives when they are technologically equivalent and socio-economically sustainable. Products containing S-SVHC that can not be substituted must should be used under strictly controlled conditions (SCC).

Yes, Syensqo uses an indicator to follow the progress on the above target (% of safer alternatives performed within the year for marketed products containing S-SVHC, including the review when necessary).